Early administration of the antiparasitic drug didn't shorten time to clinical improvement.
"Cumulatively, the findings suggest that ivermectin does not significantly affect the course of early COVID-19, consistent with pharmacokinetic models showing that plasma total and unbound ivermectin levels do not reach the concentration resulting in 50% of viral inhibition even for a dose level 10-times higher than the approved dose," the authors concluded.
"The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes."
Further, a paper that had been accepted that appeared to be positive was withdrawn, citing numerous issues with the paper, including "“a series of strong, unsupported claims based on studies with insufficient statistical significance, and at times, without the use of control groups.”
A review article containing contested claims about the tropical medicine drug as a COVID-19 treatment was listed as "provisionally accepted" on the journal's website before being removed this week.